Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Luigi GargiuloLuciano IbbaPiergiorgio MalagoliRosa Giuseppa AngileriFederico BardazziNicoletta BernardiniMartina BurlandoCarlo G CarreraAndrea ChiricozziPaolo DapavoValentina DiniGabriella FabbrociniFrancesca Maria GaianiMarco GalluzzoClaudia GiofréClaudio GuarneriFrancesco LoconsoleGiovanna MalaraLorenzo MarcelliMatteo MegnaStefano PiasericoMarina TalamontiAntonio CostanzoAlessandra NarcisiPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in 'real-life' clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.